Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3068% above fair value
$7.40+0.49 (+7.09%)
Close on Nov 20, 2026Market cap $204.25MP/E –Yield –
Precision BioSciences net income
Net income is the profit left for shareholders after every expense, interest and tax.
Precision BioSciences's net income for the twelve months ending Jun 30, 2026 was -$52.73M. For fiscal 2025 it was -$45.72M, down 738.0% from the year before. The highest annual figure on record is $7.17M in fiscal 2024.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.72M | -738.0% |
| FY2024 | Dec 31, 2024 | $7.17M | – |
| FY2023 | Dec 31, 2023 | -$61.32M | – |
| FY2022 | Dec 31, 2022 | -$111.64M | – |
| FY2021 | Dec 31, 2021 | -$30.60M | – |
| FY2020 | Dec 31, 2020 | -$109.01M | – |
| FY2019 | Dec 31, 2019 | -$92.88M | – |
| FY2018 | Dec 31, 2018 | -$46.04M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.65M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.44M | – |
| Q4 FY2025 | Dec 31, 2025 | $20.13M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.52M | -171.8% |
| Q1 FY2025 | Mar 31, 2025 | -$20.57M | -339.5% |
| Q4 FY2024 | Dec 31, 2024 | -$17.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.43M | – |
| Q2 FY2024 | Jun 30, 2024 | $32.75M | – |
| Q1 FY2024 | Mar 31, 2024 | $8.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.06M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$31.04M | -243.3% |
| Q1 FY2022 | Mar 31, 2022 | -$28.17M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.28M | – |
| Q2 FY2021 | Jun 30, 2021 | $21.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.69M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$32.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.84M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$20.74M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.44M | – |
| Q1 FY2019 | Mar 31, 2019 | -$31.78M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.44M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.76M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.83M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.01M | – |
See a number that looks wrong?